Comparison of Reporting of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Selective COX-2 Inhibitors
- 1 January 2005
- journal article
- research article
- Published by Springer Nature in Drug Safety
- Vol. 28 (10) , 917-924
- https://doi.org/10.2165/00002018-200528100-00008
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Thalidomide: dermatological indications, mechanisms of action and side-effectsBritish Journal of Dermatology, 2005
- A marker for Stevens–Johnson syndromeNature, 2004
- Evaluation of the Extent of Under-Reporting of Serious Adverse Drug ReactionsDrug Safety, 2004
- Toxic Epidermal Necrolysis Due to Administration of Celecoxib (Celebrex)Southern Medical Journal, 2003
- Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?BMJ, 2002
- The Coxibs, Selective Inhibitors of Cyclooxygenase-2New England Journal of Medicine, 2001
- COX-2 inhibitorsThe Lancet, 1999
- Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal NecrolysisNew England Journal of Medicine, 1995
- Severe Adverse Cutaneous Reactions to DrugsNew England Journal of Medicine, 1994
- Power and weakness of spontaneous reporting: A probabilistic approachJournal of Clinical Epidemiology, 1992